Skip to main content

Table 3 Treatment response to apatinib monotherapy or combination therapy

From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression

  Monotherapy response (n, %) Combination therapy response (n, %) Overall response (n, %)
Complete response (CR) 0 (0%) 0 (0%) 0 (0%)
Partial response (PR) 6 (21.43%) 7 (53.85%) 13 (31.71%)
Stable disease (SD) 17 (60.71%) 2 (15.38%) 19 (46.34%)
Progressive disease (PD) 5 (17.86%) 4 (30.77%) 9 (21.95%)
Objective response rate (ORR) 6 (21.43%) 7 (53.85%) 13 (31.71%)
Disease control rate (DCR) 23 (82.14%) 9 (69.23%) 32 (78.05%)